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Background: Despite the improvement in detection and surgical therapy in the last years, the outcome of patients
affected by colorectal carcinoma (CRC) remains limited by metastatic relapse. The aim of this study was to investigate
the presence of free tumor DNA in the plasma of CRC patients in order to understand its possible prognostic role.
Patients and methods: Ki-Ras, TP53 mutations and p16INK4A methylation status were prospectively evaluated in
tumor tissues and plasma of 66 CRC patients.
Results: In 50 of the 66 primitive tumor cases (76%) at least one significant alteration was identified in Ki-Ras and/or
TP53 and/or p16INK4A genes. Eighteen of the 50 patients presented the same alteration both in the plasma and in the
tumor tissue. At univariate analysis, Ki-Ras mutations proved to be significantly related to quicker relapse (P <0.01),
whereas only a trend towards statistical significance (P = 0.083) was observed for the TP53 mutations
Conclusions: Detection of Ki-Ras and TP53 mutation in plasma should be significantly related to disease
recurrence. These data suggest that patients with a high risk of recurrence can be identified by means of the analysis
of tumor-derived plasma DNA with the use of fairly non-invasive techniques.
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introduction
Colorectal carcinoma (CRC) is one of the most common solid
tumors in the Western world, with over 300 000 cases occurring
every year in the USA and in Europe and a mean 5-year survival
rate of 50% [1]. In spite of the progress made in the last few
years with regard to early diagnosis and surgical treatment,
30%–50% of patients who undergo radical surgery develop
a subsequent relapse leading to death [2].
The presence of fragments of circulating DNA has been
described many times in different body fluids. A large number
of studies conducted on the plasma and serum of patients
with cancer of the pancreas, colon, breast, liver, head and
neck, and esophagus, have shown that such subjects have
a higher level of circulating DNA fragments than healthy
subjects. No clear correlation has been established, however,
either between circulating DNA levels and the size and site of
the tumor, or, so far, between these levels and the clinical
course of the disease [3, 4]. In addiction most of the
circulating DNA would appear to originate from the
primary tumor since the plasma shows the same genetic
alterations [2].
Colorectal carcinogenesis is characterized by genetic
alterations of the oncogenes and oncosuppressors, especially of
the Ki-Ras and TP53 genes [5]. These alterations might become
useful markers for the detection of tumor DNA in the plasma of
patients with this disease.
It has recently been observed that the hypermethylation of the
normally non-methylated CpG islands in the p16INK4A gene
promoter is correlated with its transcription level in various
tumors. The inactivation of this gene subsequent to aberrant
methylation has been reported in 20%–50% of CRCs [6]. The
presence of epigenetic alterations of the oncosuppressor
p16INK4A might therefore be used as a tumoral marker in the
plasma of patients with such tumors [7].
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The aim of this study was to support the diagnostic and
prognostic value of circulating DNA detected in the plasma of
patients affected by CRCs. The genetic alterations of the
oncogene Ki-Ras, of the tumor suppressor gene TP53 and the
methylation status of the p16INK4A gene promoter were analyzed
in the primary tumors of 66 patients with CRC; in patients
where such alterations were identified, analysis of their plasma
was performed in order to detect the same genetic alterations.
Finally, it has been assessed whether or not the presence of
tumor-associated circulating DNA might be used as a marker
for the identification of patients with a more unfavorable
prognosis and/or disease relapse risk.
patients and methods
patient selection
A prospective study was performed on a consecutive series of 66 patients
undergoing resective surgery for primary operable CRC at a single
institution (Department of Oncology, University of Palermo).
In these patients it was possible to take a pre-operative blood sample, the
primary tumor tissue and normal mucosa. Inclusion criteria were:
histologically-confirmed CRC diagnosis; and patients undergoing radical
surgery with resection margins histologically negative for neoplastic
infiltration. Clinicopathological variables of the patients were age, sex,
tumor stage, histological grading and tumor size. The mean age of the
patients at diagnosis was 66 ± 11 years and the group was made up of 34 men
and 32 women. Up to the present time, all the patients are undergoing
regular follow-up. Staging was performed according to the TNM
classification. The tumors were divided into three groups according to the
WHO criteria: well-differentiated (grade 1), moderately differentiated
(grade 2) and poorly differentiated (grade 3). Twenty blood samples of
healthy subjects and seven non-neoplastic gastrointestinal tissue were
analyzed for the same alterations as controls.
sampling, DNA extraction and analysis of the genic
status of Ki-Ras and of TP53 in the primary tumor tissue
The samples of primary tumor and normal tissue were stored at –80C until
required. Genomic DNA was extracted by means of the QIAamp kit
(Qiagen, Hilden, Germany), following the standard protocol. The DNA
samples were used to screen for mutations within the TP53 and Ki-Ras genes
using Single Strand Conformational Polymorphism (SSCP) analysis. PCR
amplification of the exons 5–8 for TP53 and exon 1 for Ki-Ras (Table 1) was
performed as previously described [9]. The abundance and integrity of the
amplification products were verified by 1.5% agarose gel electrophoresis and
ethidium bromide staining. One hundred nanogram aliquots of the PCR
products, purified and concentrated by filtration through Microcon 50
columns (Amicon, Beverly, MA), were denatured and used for SSCP
analysis. Individual ssDNA fragments exhibiting shifted mobilities relative to
normal controls, were electroeluted from polyacrylamide gel, as described
previously [10], reamplified and sequenced. The characterization of single
mutations was performed by automated sequencing using the Big Dye
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and
the model 3100 GeneticAnalyzer sequencer (Perkin-Elmer, Foster City, CA).
sampling, DNA extraction and mutational analysis of
the plasma
The plasma sample was obtained by centrifuging 3 ml of peripheral blood at
1550 g for 30 min. An aliquot was prepared from the resulting supernatant
and was stored at –20C until required. Genomic DNA was extracted by
means of an Ultrasense Virus Kit (Qiagen, Hilden Germany), according to
the standard protocol. Direct automatic sequencing was used to detect the
same genetic alterations in the plasma.
methylation status of p16INK4A locus
Genomic DNA obtained from plasma, normal and tumor tissue samples was
modified with the CpGenome DNA Modification kit (Intergene Company)
following the manufacturer’s instructions [10]. Peripheral blood leukocytes
(L) were used as negative controls and universal methylated DNA,
UMD (ONCOR, Geithersburg, MD) was used as a positive control. The
modified DNA was amplified by PCR using specific primers (Table 1) to
distinguish between methylated and unmethylated regions. The size and
integrity of the amplification products were verified by 2% agarose gel
electrophoresis and ethidium bromide staining.
statistical analysis
Association between biological and clinicopathological variables was
evaluated by means of the chi-square test and, where appropriate, Yates’
correction. Disease-free survival (DFS) was measured from the day of
primary surgery to the date of first relapse (locoregional or metastatic) and
overall survival (OS) from the day of surgery to the day of death. If patients
did not relapse or die, they were censored at the time of their last follow-up.
Clinical and morphobiological variables were examined by means of the
Kaplan–Meier method; significance of differences for each prognostic factor
was assessed by the log rank and Wilcoxon tests or trend tests where
appropriate.
results
detection of genetic alterations in colorectal
cancer tissue
Genetic alterations in Ki-Ras and TP53 were performed with the
PCR-SSCP techniques. The sequence analysis of the DNA
fragments with altered electrophoretic mobility helped to
establish the exact site and nature of the genetic alteration.
Hypermethylation of the p16INK4A gene promoter were
performed with MSP of bisulfite modified DNA.
In 50 of the 66 cases (76%) at least one significant alteration
was identified. Twenty-nine of the 66 cases (44%) showed
Table 1. Oligonucleotide primers for p53, H-ras, K-ras and p16 genotyping
Exon Primer sequences Anneal (C)
ex5 p53 59-caa cca gcc ctg tcg tct ctc-39 58
59-ctg ttc act tgt gcc ctg ac-39
ex6 p53 59-cct cac tga ttg ctc tta gg-39 50
59-agt tgc aaa cca gac ctc a-39
ex7 p53 59-caa gtg gct cct gac ctg ga-39 58
59-tcc tag gtt ggc tct gac-39
ex8 p53 59-tcc tgc ttg ctt acc tcg-39 54
59-tcc tat cct gag tag tgg t-39
h-ras 59-ctg agg agc gat gac gga ata taa gc-39 68
59-ctc tat agt ggg gtc gta ttc gtc ca- 39
k-ras 59-gtg tga cat gtt cta ata tag tca ca-39 58
59-gaa tgg tcc tgc acc agt aa -39
p16M 59-tta tta gag ggt ggg gcg gat cgc-39 61
59-gac ccc gaa ccg cga ccg taa-39
p16U 59-tta tta gag ggt ggg gtg gat tgt-39 66
59-cca ccc caa acc aca acc ata a-39
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hot-spot mutations of Ki-Ras gene after sequencing: 21 in codon
12 and eight in codon 13.
Aberrantly migrating bands of exons 5–8 of the TP53 gene
were found in 41% (27/66) of the cases; sequence analysis was
performed in only 20 tumor samples (Figure 1). The 27
nucleotidic alterations were made up of five in exon 5 (19%), six
in exon 6 (22%), nine in exon 7 (33%) and seven in exon 8
(26%). Two mutation were frameshifts while the majority of the
mutations were single nucleotide substitutions. Sixty-seven per
cent of the latter were missense (12/18), 28% were silent
mutations or polymorphisms (5/18) and 5% were nonsense
mutations (1/18). Fifty per cent of the mutations (10/20)
occurred in conserved domains (areas II–V). In addition, by
taking into account the specific functional and structural
domains of TP53 affected by the mutations, the latter were
classified as follows: two of 20 cases (10%) with mutations of
the L2, three of 20 cases (15%) with mutations of the LSH motif
and five of 20 cases (25%) with mutations of the L3 (Figure 2).
Since the polymorphism do not determine any amino acid
change in the protein, for statistical analysis they have been
included in the wild-type group.
The analysis of the p16INK4A gene promoter showed that 14/
66 cases (21%) presented hypermethylation; the analysis of the
normal tissue of the same patients did not reveal
hypermethylation (Figure 3).
Multiple alterations were found in 20% (13/66) of the
analyzed CRC cases. Eleven cases presented double mutations;
four cases (200/110, 200/18, 200/187 and 200/1817) presented
the hypermethylation of the p16INK4A promoter and Ki-Ras
mutation, two cases (200/48, 200/71) presented the
hypermethylation of the p16INK4A promoter and TP53
mutation, and four cases (200/70, 200/267, 200/275 and 200/
288) presented both TP53 and Ki-Ras mutations. One case
(200/65) was found to harbor two mutations in two different
exons (7–8) of TP53. Two cases (200/01 and 200/142) presented
a triple mutation: the hypermethylation of the p16INK4A
promoter and mutations of Ki-Ras and TP53. Table 2 shows the
results of the genetic alterations analyzed in all the patients.
Exactly the same analyses were performed on the control
group; no genetic or epigenetic alterations were detected.
detection of tumor DNA in the plasma
The second step of this study was to detect in plasma samples
the same alteration found in the corresponding tumor tissues;
only 76% of patients (50/66) were therefore selected.
Eighteen of the 50 patients (36%) presented the same
alteration both in the plasma and in the tumor tissue, eight of
which mutated in Ki-Ras and eight in TP53. In four cases the
amplifications with the primers for Ki-Ras and/or TP53 failed
and the alterations were thus considered unreliable.
Hypermethylation of p16INK4A gene promoter was detected in
the plasma of three of 18 patients (17%) (Table 2). Multiple
alterations were found in plasma of three cases.
relationship between plasma biomolecular
indicators and clinical data
No significant correlations were observed between gender, age,
tumor site and tumor stage and the detection of free-circulating
tumor-associated DNA (data not shown).
relationship between detection of tumor DNA in
plasma and prognosis
At the time of this report, 21/50 patients have relapsed, 18 with
distant metastases and three with locoregional recurrence, while
10/50 have died from tumor-related causes. The median follow-
up time in our study group was 26 months (range 2–48
months). At univariate analysis, Ki-Ras mutations proved to be
significantly related to quicker relapse (P <0.01), whereas only
a trend towards statistical significance (P = 0.083) was observed
for the TP53 mutations (Figure 4). No significant association
has been identified between the same genetic alteration and the
Figure 2. TP53 structure showing the five areas highly conserved during evolution and the most important functional domains of the protein [5].
Figure 1. SSCP analysis of exon 7 of TP53 gene amplified from DNA of
primitive tumor (case 200/65) and normal tissue of the same patient: the
normal tissue DNA is on the left; tumor DNA is on the right (A). The extra
bands correspond to ssDNA molecules harboring mutations in exon7
R249S AGG>AGT as confirmed by sequencing (B).
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OS. p16INK4a promoter hypermethylation and the
clinicopathological parameters analyzed were not significantly
associated.
discussion
The mechanism leading to the presence of free tumor DNA
in the plasma of cancer patients is still not fully understood.
It might be caused by the lysis of circulating cancer cells or
by DNA leakage resulting from tumor necrosis or apoptosis
[11]. Recent studies have confirmed that somatic genetic or
epigenetic alterations in tumors are potential targets for
molecular investigation in plasma [12]. The aim of this study
was to confirm the hypothesis that molecular markers may be
used today in the early diagnosis and prognosis of patients
affected by CRC. Therefore, the genetic and epigenetic
alterations characterized in the CRC were analyzed in plasma
in order to identify a possible association.
The most commonly used target was Ki-Ras, which is
mutated in a large number of gastrointestinal tumors.
Figure 3. p16INK4a analysis using MSP in case 200/71. MSP results are
expressed as unmethylated (U) or methylated (M) p16INK4A specific bands.
Normal lymphocytes (L) and in vitro universal methylated DNA (UMD)
are used as negative and positive controls, respectively. Case 200/71 shows
hypermethylated of p16INK4A promoter within the primitive tumor (K),
but not in plasma (P). The last lane contains 100 bp DNA ladder.
Table 2 Aberrant p16 methylathion and TP53 and K-Ras mutation in the tumors and plasma DNA of colorectal cancer patients
Patient no. Stage (Dukes) TP53 Ki-Ras p16
DNA Tumor DNA Plasma DNA Tumor DNA Plasma DNA Tumor DNA Plasma
200/01 1 Mut ex5 Mut ex5 Mut ex1 G12N Mut ex1 G12N M U
200/13 1 WT WT M U
200/141 1 WT WT M U
200/145 1 WT WT U
200/146 1 WT WT U
200/16 1 Pol ex6 R213R Mut ex1 G12V WT U
200/28 1 Pol ex6 R213R Mut ex1 G12V Mut ex1 G12V U
200/196 1 Mut ex5 WT WT U
200/202 1 WT WT U
200/77 1 WT WT M U
200/87 1 WT WT U
200/91 1 Pol ex7 D228D WT U
200/240 1 WT WT U
200/245 1 WT Mut ex1 G12s WT U
200/257 1 WT Mut ex1 G12V WT U
200/267 1 Mut ex7 R249S WT Mut ex1 G12N WT U
200/275 1 Mut ex7 A244D Mut ex7 A244D Mut ex1 G12V np U
200/293 1 WT Mut ex1 A13N np U
200/66 2 Mut ex8 R282P Mut ex8 R282P WT U
200/69 2 WT Mut ex1 G13C U
200/70 2 Mut ex7 Mut ex7 Mut ex1 G12V Mut ex1 G12V U
200/71 2 Mut ex7 Mut ex7 WT M U
200/80 2 WT WT U
200/105 2 Pol ex6 R213R Mut ex1 G12V WT U
200/123 2 WT WT U
200/26 2 WT Mut ex1 G12V WT U
200/1817 2 WT Mut ex1 G13C WT M M
200/182 2 WT Mut ex1 G13C WT U
200/1822 2 WT WT M M
200/58 2 WT Mut ex1 G12S WT U
200/265 2 Mut ex8 792delCTA WT WT U
200/276 2 Mut ex8 R306X WT WT U
200/288 2 Mut ex8 R282W WT Mut ex1 G12N np U
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In particular, the CRC showed Ki-Ras mutations in 20%–50%
of the cases [13]. In agreement with reported data, the results of
our study show that 44% of Ki-Ras mutations in primary
tumors are detected in the hot spots.
Point mutations in the TP53 tumor suppressor gene are the
most common cancer-related genetic abnormality in human
malignancy. Previous analyses of different types of tumors have
shown that most of TP53 mutations affect exons 5–8, especially
residues 130–286 encoding TP53 DNA-binding domain. Only
rarely have mutations outside exons 5–8 been identified,
including those in the introns of the splicing sites, which
probably give rise to an aberrant RNA splicing [14]. In
agreement with reported data, our study shows 41% of TP53
mutations in primitive tumors.
Methylation changes are sometimes associated with the
ageing of normal epithelium but a new generation of studies is
beginning to investigate the prognostic significance of the
methylation of multiple genes in cancer. Only those methylation
markers, which are always unmethylated in normal cells such as
the oncosuppressor genes, might, therefore, be potentially useful
for cancer detection [15]. Hypermethylation of the p16INK4A
promoter has been reported in many primary tumors such as
those of the esophagus, the lung, the cervix, and the colon,
where it was found in 20%–40% [16]. In our study, 21% of the
patients show p16 INK4A hypermethylation in tumor DNA.
Furthermore, the hypermethylation observed by us did not
appear to be age-related, since the normal tissue of the same
patients showed no alteration. All the results of the analyses
performed were in agreement with reported data.
The use of the three molecular markers seems to be
extremely useful since this made it possible to detect
free-circulating tumor-associated DNA in 76% of the
patients. The results of our study confirm that it is possible
to identify Ki-Ras, TP53 and the hypermethylation of the
p16INK4A promoter alterations in DNA extracted from the
pre-operative plasma of patients with colorectal cancer, and
that PCR-SSCP and MSP are extremely sensitive methods for
this [17, 18]. In fact, 38% of the patients with mutated
Table 2. (Continued)
Patient no. Stage (Dukes) TP53 Ki-Ras p16
DNA Tumor DNA Plasma DNA Tumor DNA Plasma DNA Tumor DNA Plasma
200/294 2 Mut ex5 R175P WT WT U
200/304 2 Mut ex6 R213L np WT U
200/327 2 Mut ex5 R175C WT WT U
200/03 3 WT Mut ex1 G13A Mut ex1 G13A U
200/06 3 WT WT M U
200/09 3 WT WT U
200/65 3 Mut ex8 R283P Mut ex8 R283P WT U
Mut ex7 R249S Mut ex7 R249S
200/101 3 Mut ex8 WT WT U
200/110 3 WT Mut ex1 G12N WT M U
200/142 3 Mut ex7 R248W WT Mut ex1 G12N WT M U
200/143 3 Mut ex8 WT WT U
200/18 3 WT Mut ex1 G12N Mut ex1 G12N M U
200/1816 3 WT WT U
200/1821 3 WT WT M M
200/1845 3 WT WT U
200/187 3 WT Mut ex1 G13A Mut ex1 G13A M U
200/48 3 Mut ex8 S576H WT WT M U
200/52 3 Mut ex7 Mut ex7 WT U
200/53 3 WT Mut ex1 G12N Mut ex1 G12N U
200/56 3 WT Mut ex1 G13C Mut ex1 G13C U
200/209 3 WT WT U
200/218 3 WT WT U
200/219 3 WT Mut ex1 G12A WT U
200/228 3 WT WT U
200/229 3 WT Mut ex1 G13A WT U
200/260 3 WT Mut ex1 G12N WT U
200/262 3 WT Mut ex1 G12V WT U
200/290 3 Pol ex6 R213R Mut ex1 G12S U
200/305 3 Mut ex6 634delTT WT WT U
200/83 4 WT Mut ex1 G12V WT U
200/211 4 WT WT U
200/227 4 Mut ex7 R248W WT WT U
200/270 4 WT WT U
WT, wild type; Mut, mutation; Pol, polymorphism; U, unmethylated; M, methylated; np, no product; ex, exon.
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Ki-Ras in the tumor tissue showed the same alteration
in the plasma, 30% showed an alteration in TP53 and
17% presented hypermethylation of the p16INK4A gene
promoter.
Very few data are available concerning the prognostic impact
of plasma tumor DNA in cancer patients. Several studies, in fact,
have demonstrated that plasma tumor-associated alterations in
the Ki-Ras gene could predict surgical resectability and
prognosis in pancreatic cancer patients [19]. A preliminary
study conducted in CRC patients showed who were positive for
Ki-Ras mutations in plasma DNA, were more likely to have large
tumors and were less likely to have curative resection than those
who were negative for plasma DNA mutations [12]. In our
study the statistical analysis performed on the three variables
considered independent has shown that Ki-Ras and TP53
mutations are significantly related to disease recurrence.
In conclusion, our data suggest that patients with high risk of
recurrence can be identified by means of the analysis of tumor-
derived plasma DNA with the use of fairly non-invasive
techniques. Nevertheless, further studies are needed to reach
a clearer understanding of the mechanisms leading to the
presence of free-circulating tumor-associated DNA in the
plasma. Genetic alterations in cancer DNA can be used to
identify early cancers and it would be interesting to study the
variation in circulating tumor DNA levels in relation to cancer
treatment and patient prognosis [20].
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